A study to evaluate the efficacy of L-carnitine injection in dialysis patients with complications

A study to evaluate the efficacy of L-carnitine injection in dialysis patients with complications - A study to evaluate the efficacy of L-carnitine injection in dialysis patients with complications

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011313

Enrollment

100

Registered

2013-08-01

Start date

2013-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic kidney disease

Interventions

L-carnitine injection 1000mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who receive three times a week of hemodialysis more than one year. Patients who has not received carnitine medication for six month before this study. Patients who are under treatment of renal anemia with ESA. Patients who meet the criteria of the carnitine deficiency. Patients providing written informed consent.

Exclusion criteria

Exclusion criteria: Patients known to have a history or complication of allergy to L-carnitine. Women who are pregnant or possibly pregnant. Patients who are judged to be inappropriate to this study.

Design outcomes

Primary

Measure	Time frame
Usage dose of ESA	—

Secondary

Measure	Time frame
serum carnitine concentration, QOL, muscle symptoms, inflammatory marker, nutritional status, cardiothoracic ratio, adverse events	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026